Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MGTX |
---|---|---|
09:32 ET | 668 | 4.2 |
09:36 ET | 200 | 4.25 |
09:38 ET | 400 | 4.22 |
09:50 ET | 500 | 4.265 |
09:57 ET | 500 | 4.26 |
10:01 ET | 3200 | 4.34 |
10:03 ET | 1200 | 4.29 |
10:06 ET | 400 | 4.26 |
10:12 ET | 1298 | 4.19 |
10:14 ET | 293 | 4.19 |
10:15 ET | 1159 | 4.151 |
10:17 ET | 425 | 4.1702 |
10:19 ET | 235 | 4.175 |
10:32 ET | 500 | 4.2 |
10:35 ET | 900 | 4.23 |
10:42 ET | 601 | 4.18 |
10:44 ET | 200 | 4.19 |
10:46 ET | 100 | 4.18 |
10:55 ET | 109 | 4.14 |
10:57 ET | 434 | 4.16 |
11:02 ET | 100 | 4.1573 |
11:15 ET | 103 | 4.14 |
11:20 ET | 100 | 4.12 |
11:27 ET | 235 | 4.11 |
11:31 ET | 800 | 4.1123 |
11:38 ET | 681 | 4.08 |
11:42 ET | 117 | 4.08 |
11:51 ET | 104 | 4.09 |
12:00 ET | 200 | 4.1 |
12:02 ET | 900 | 4.11 |
12:03 ET | 100 | 4.13 |
12:05 ET | 200 | 4.13 |
12:07 ET | 1577 | 4.135 |
12:23 ET | 1575 | 4.13 |
12:30 ET | 245 | 4.1467 |
12:32 ET | 1000 | 4.11 |
12:43 ET | 100 | 4.112 |
12:48 ET | 283 | 4.11 |
12:57 ET | 600 | 4.09 |
12:59 ET | 311 | 4.09 |
01:01 ET | 352 | 4.1 |
01:06 ET | 100 | 4.1 |
01:28 ET | 1000 | 4.09 |
01:30 ET | 100 | 4.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MeiraGTx Holdings PLC | 270.7M | -3.2x | --- |
Molecular Partners AG | 266.2M | -3.5x | --- |
Uniqure NV | 217.5M | -0.7x | --- |
XOMA Corp | 275.7M | -6.0x | --- |
TScan Therapeutics Inc | 309.2M | -4.4x | --- |
C4 Therapeutics Inc | 317.9M | -1.9x | --- |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $270.7M |
---|---|
Revenue (TTM) | $11.4M |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.33 |
EPS | $-1.27 |
Book Value | $2.17 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 23.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.